Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	55.55	36.67	26.4	29.15	8.41
Short-Term Investments	306.56	118.85	175.73	219.27	267.26
Cash & Cash Equivalents	362.11	155.52	202.14	248.42	275.67
Cash Growth	132.84%	-23.06%	-18.63%	-9.89%	-8.58%
Other Current Assets	5.11	11.52	8.39	7.69	7.83
Total Current Assets	367.23	167.04	210.53	256.1	283.5
Property, Plant & Equipment	1.13	1.42	0.03	0.32	0.6
Other Long-Term Assets	0.14	0.07	0.11	0.08	0.16
Total Long-Term Assets	1.27	1.49	0.13	0.4	0.76
Total Assets	368.49	168.53	210.66	256.5	284.26
Accounts Payable	7.51	8.53	1.44	3.99	2.43
Current Debt	0.32	0.3	0.03	0.33	0.3
Other Current Liabilities	11.3	13.11	7.31	7.81	4.04
Total Current Liabilities	19.14	21.95	8.78	12.13	6.78
Long-Term Debt	0.94	1.26	0	0.03	0.36
Total Long-Term Liabilities	0.94	1.26	0	0.03	0.36
Total Liabilities	20.07	23.21	8.78	12.16	7.14
Total Debt	1.26	1.56	0.03	0.36	0.66
Debt Growth	-19.44%	5293.10%	-91.92%	-45.77%	-
Retained Earnings	-377.94	-292.05	-223.18	-168.19	-128.7
Comprehensive Income	-0.39	-1.1	-0.55	-0.05	0.01
Shareholders' Equity	348.42	145.32	201.88	244.34	277.12
Net Cash / Debt	360.85	153.95	202.11	248.06	275.01
Net Cash / Debt Growth	134.39%	-23.83%	-18.52%	-9.80%	-8.80%
Net Cash Per Share	3.82	2.00	2.62	3.42	3.82
Working Capital	348.09	145.09	201.75	243.98	276.72
Book Value Per Share	3.69	1.89	2.62	3.37	3.85

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).